νμ μ§λ°©μ° (μ€λ©κ°-3 / μ€λ©κ°-6)
νμ μ§λ°©μ°(EFA)μ 체λ΄μμ ν©μ±λμ§ μμ μλ¨μ ν΅ν΄ μμ·¨ν΄μΌ νλ λ€μ€λΆν¬ν μ§λ°©μ λλ€. μμνμμλ μ£Όλ‘ νμΌμ¦ νΉμ±μ νμ©νμ¬ νΌλΆ, μ¬νκ΄, μ μ₯ λ° κ΄μ 건κ°μ μ§μνλ λ° μ¬μ©λ©λλ€. * **μ€λ©κ°-3 μ§λ°©μ°**(EPA, DHA)μ μΌλ°μ μΌλ‘ ν΄μ 곡κΈμ(μ΄μ )μμ μΆμΆλλ©° μΌμ¦μ μ€μ΄λ κ²μΌλ‘ μλ €μ Έ μμ΅λλ€. * **μ€λ©κ°-6 μ§λ°©μ°**(리λλ μ°)μ ννΌ μ§μ§ μ₯λ²½κ³Ό νΌλͺ¨ νμ§μ μ μ§νλ λ° μ€μν©λλ€. > **μμ μμ :** νλμ λ°λ €λλ¬Ό μλ¨μ μ€λ©κ°-6μ μΉμ°μΉ κ²½μ°κ° λ§μ, 골κ΄μ μΌ, μν νΌ, λ§μ± μ μ₯ μ§νκ³Ό κ°μ μΌμ¦μ± μ§νμ κ΄λ¦¬ν λ μ€λ©κ°-3 λ³΄μΆ©μ΄ λ§€μ° μ μ΅ν©λλ€.
μμ© κΈ°μ : **Omega-3s (EPA/DHA)** compete with arachidonic acid (an Omega-6) for the enzymes **cyclooxygenase (COX)** and **lipoxygenase (LOX)**. * EPA/DHA β COX/LOX β Production of less inflammatory eicosanoids (e.g., 3-series prostaglandins and 5-series leukotrienes) instead of the highly inflammatory 2-series prostaglandins and 4-series leukotrienes. * **Omega-6s (Linoleic Acid)** β incorporated into the stratum corneum β improves water barrier function and reduces transepidermal water loss (TEWL).
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Patients with a history of pancreatitis
- Patients with bleeding disorders (use with caution)
μ΄μλ°μ
- Gastrointestinal upset (diarrhea, vomiting)
- Weight gain
- Altered platelet function (high doses)
- Pancreatitis (rare, in susceptible individuals due to fat content)
μ½λ¬Ό μνΈμμ©
- Anticoagulants (e.g., Heparin, Warfarin) Β· May increase risk of bleeding due to altered platelet aggregation
- NSAIDs Β· Synergistic anti-inflammatory effect (often beneficial, allowing for lower NSAID doses)
λͺ¨λν°λ§
- Clinical response (improvement in coat, mobility, or renal values)
- Fecal consistency
- Signs of bleeding (if on high doses)
κ³Όμ©λ
Acute overdose may cause significant gastrointestinal distress, including vomiting, diarrhea, and potentially pancreatitis. Chronic massive overdose may lead to coagulopathies or delayed wound healing. Treatment is supportive.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.